Jeffrey L. Wade - 28 Feb 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
President and CFO
Signature
/s/ Jeffrey L. Wade
Issuer symbol
LXRX
Transactions as of
28 Feb 2023
Net transactions value
-$65,653
Form type
4
Filing time
01 Mar 2023, 15:48:08 UTC
Previous filing
13 Feb 2023
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +30,467 +16% 224,147 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +11,176 +5% 235,323 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +37,273 +16% 272,596 28 Feb 2023 Direct F1
transaction LXRX Common Stock Tax liability $65,653 -30,255 -11% $2.17 242,341 28 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -30,467 -100% 0 28 Feb 2023 Common Stock 30,467 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -11,176 -50% 11,177 28 Feb 2023 Common Stock 11,176 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -37,273 -33% 74,547 28 Feb 2023 Common Stock 37,273 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.